Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

In this this dynamic program on the optimal treatment of patients with relapsed or refractory HER2-positive advanced breast cancer, renowned breast cancer experts review and discuss key clinical data and patient case studies and look ahead at promising agents that may soon change practice.
Adam M. Brufsky, MD, PhD
person default
Cristina Saura, MD, PhD

ClinicalThought

How confident are you in managing patients who experience interstitial lung disease while receiving trastuzumab deruxtecan?

Adam M. Brufsky, MD, PhD Released: September 10, 2020

Read expert answers to audience questions from a CCO Webinar on current best practices and emerging options for patients with HER2-positive MBC.

person default Cristina Saura, MD, PhD Released: September 11, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?